EP3146956A1 - Dispositif de distribution de medicaments et corps de base, tiroir a medicament et module d'extension pour un dispositif de distribution de medicaments - Google Patents

Dispositif de distribution de medicaments et corps de base, tiroir a medicament et module d'extension pour un dispositif de distribution de medicaments Download PDF

Info

Publication number
EP3146956A1
EP3146956A1 EP15186599.5A EP15186599A EP3146956A1 EP 3146956 A1 EP3146956 A1 EP 3146956A1 EP 15186599 A EP15186599 A EP 15186599A EP 3146956 A1 EP3146956 A1 EP 3146956A1
Authority
EP
European Patent Office
Prior art keywords
compartment
interior
base body
delivery device
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15186599.5A
Other languages
German (de)
English (en)
Other versions
EP3146956B1 (fr
Inventor
Angelika Schulten
Alexander Burgwedel
Matthias Menzel
Simon Gorski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Han-Buerogeraete & Co KG GmbH
Original Assignee
Amts-System GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amts-System GmbH filed Critical Amts-System GmbH
Priority to ES15186599T priority Critical patent/ES2741318T3/es
Priority to EP15186599.5A priority patent/EP3146956B1/fr
Publication of EP3146956A1 publication Critical patent/EP3146956A1/fr
Application granted granted Critical
Publication of EP3146956B1 publication Critical patent/EP3146956B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0076—Medicament distribution means
    • A61J7/0084—Medicament distribution means for multiple medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers

Definitions

  • the present invention relates to a drug delivery device, as well as a base, drug compartments and expansion modules for a drug delivery device.
  • dispensers ie classic "pill boxes”
  • manual or machine Neu-blistering ie classic "pill boxes”
  • dispensers ie classic "pill boxes”
  • manual or machine Neu-blistering ie classic "pill boxes”
  • these techniques can be used for certain chemically and mechanically stable drugs, but are completely unsuitable for many drugs in other dosage forms or sensitivities, such as drops, ointments or airway sprays.
  • 30 to 60 percent of all drugs can neither be blistered, nor fit into one Pill box (DBfK, 2011).
  • the previous techniques thus always require an additional "system next to the system", which considerably reduces the handling and the overview.
  • biologics which are referred to as "large molecules” have become increasingly important in drug therapy. Due to their chemical and physical properties, they are particularly sensitive and thus completely eliminated for storage in dispensers or for the process of re-blistering.
  • dispensers In the case of dispensers, it is furthermore particularly disadvantageous that these usually follow a very general intake or application pattern (eg "morning-noon-evening-night"), but that individually therapeutically highly relevant finer intake or application times (eg “pre-accession”). after a meal ”) can not be easily mapped, which can be a significant enticement to wrong taking time and thus in many cases may result in loss of effect or damage.
  • conventional dispensers typically have to be filled with relatively great effort on a weekly basis, which represents another significant source of error.
  • the terms ingestion, taking pattern, time of taking in, and the like are as follows. (strictly speaking, referring to tablets and the like) and application, application pattern, time of application, and the like. (eg for patches or ointments) are used synonymously, so that is included in naming the one term, the other.
  • the re-blistering leads to the same-looking packaging of different drugs, which means that the actual contents of the original packaging can no longer be consciously perceived by the nursing staff and / or the patient. As a result, a causal relationship between the administration and the success of the therapy can no longer be established; the medicines are simply distributed, whereby the actual goal, namely a high quality of care, is missed.
  • the de-skilling of nurses associated with the re-blistering is clearly rejected by experts and according to independent studies by more than two-thirds of nurses today. Although it is sometimes believed that the re-blistering can save a great deal of money, it does show that such savings are not primarily due to the re-blistering itself but, for example, avoidance of hospitalization by concomitant medication management.
  • medicament containers are known from the prior art.
  • such systems are technically complex and therefore can be produced only with great effort.
  • the Applicant has developed a drug management system called "mediTimer stationary" specifically for use in inpatient ward offices (e.g., nursing homes, hospitals) comprising a lockable drawer with drawer for each patient.
  • the compartment division here consists of double compartments that can hold all medicines in their original packaging and an additional storage compartment.
  • this system is only suitable for stationary use.
  • the present invention is therefore based on the problem to provide a drug delivery device, with which a false medication and the associated significant health risks are prevented as much as possible. Furthermore, it is desirable that such a device allow for protected storage of drugs, be flexibly adapted to the patient's individual needs, be easy to handle, and / or applicable to a variety of drugs available on the market, and thus those referred to above at least partially overcomes disadvantages addressed by the prior art.
  • a body for a drug delivery device comprises an inner space for receiving at least one medicament compartment and a removal side for removing the at least one medicament compartment from the inner space.
  • the main body further comprises a directional presetting means, which allows the removal of the at least one medication compartment from the interior space only at the removal side.
  • the basic body according to the invention represents a "tunnel" (preferably made of plastic) in which medicament compartments (preferably also made of plastic) can be moved in the one-way street principle.
  • the main body has an interior space with one or more drug compartments, it is possible to fill this with a number of required for a specific patient medication. If, for example, the patient has to take a drug three times a day, three drug compartments are required, which are arranged in the appropriate order in the main body.
  • the predetermined collection side and the directional prescription agent ensure that the medication is taken in the correct order, because the compartments can only be pushed through the basic body in the specified direction due to the directional preselection, so that only the current compartment is removed on the withdrawal side can be. As a result, the correct revenue sequence is enforced, which losses and health damage can be prevented.
  • the automatically predetermined correct intake scheme makes it possible, for example, even older patients to use the drug delivery device according to the invention independently.
  • the interior of the base body may be a tunnel-shaped, preferably substantially parallelepiped, interior, so that the at least one medicine compartment can be arranged to move through the base body and in the direction of the removal side.
  • a cuboid interior and correspondingly shaped drug compartments for example, several drugs per compartment (ie per administration) can be stored.
  • the cuboid basic shape is also advantageous because, for example, tablet blisters are often rectangular.
  • the base body may further include a closure device near the withdrawal side, which allows removal of the at least one drug compartment only in an open position.
  • a closure device near the withdrawal side, which allows removal of the at least one drug compartment only in an open position. This makes it possible, for example, to use the drug dispenser also portable and without the risk that the drug compartments are released from the body, safely store them. Furthermore, it can be ensured by the closure device that toddlers who are typically not yet able to open such closures, get no access to the medication and thus possible incorrect revenue can be prevented.
  • the interior of the main body can have a cross-section such that the at least one medicine compartment can be arranged in the interior only in one predetermined orientation. This prevents the drug compartments from being inserted the wrong way round into the main body and thus preventing the medication from being removed.
  • At least one resilient element is used as direction setting means.
  • the medicine compartments can only be moved in one direction, so that the medicaments are taken in the correct order, since only the foremost compartment (i.e., the compartment on the withdrawal side) can be removed from the basic body.
  • the resilient element is preferably designed so that it blocks the movement performed by the patient immediately upon a shift of the drug compartments in the wrong direction, so that no medication compartment can be removed from the device.
  • the present invention may comprise a base body having dimensions, so that two, preferably three, medicine compartments can be arranged in the interior.
  • the typical intake times namely "morning noon-evening"
  • this basic body is perfectly adequate and practical for him.
  • the main body can have at least one viewing window arranged on a longitudinal side of the main body, which is arranged so that a time-of-use indicator arranged on the at least one medicament compartment is visible.
  • individually therapeutically relevant finer intake times eg at noon before eating
  • a medicament compartment for a medicament dispenser having an interior for accommodating at least one medicament in its original packaging and a directional presetting means permitting withdrawal of the medicament compartment from an interior of a body only at a withdrawal side of the body.
  • the dimensions of the interior of the medicament compartment are chosen such that at least one package of a medicament from the following group can be arranged: eg tablets, orodispersible tablets, effervescent tablets, effervescent tablets, dragees, capsules, powder capsules, drops, dosing drops, nasal spray , Juices, ampoules, ointment, shake mixture, gel, paste, emulsion, suspension, granule bag, gel bag, inhalation solution, inhalation vials, inhalation capsules, inhalation powder, inhaler, metered dose inhaler, nail varnish, deodorants, pre-filled syringes, solution for injection, Cylinder ampoules, vials and / or suspension for injection. It is understood that the present invention is basically suitable for a variety of other galenics and dosage forms.
  • the exemplified groups of drugs in their packaging can be stored compactly within the drug delivery device, thereby greatly improving handling and clarity. For example, it is possible for a patient, who has to store his medication in different places, to forget a medication, which leads to loss of effect and damage to his or her health.
  • the present invention may include a medicament compartment having an interior having a height of substantially up to 140 mm, preferably substantially up to 120 mm, more preferably substantially up to 100 mm. These dimensions allow all common sizes of original packaging to be accommodated, while at the same time keeping the drug delivery device as small as possible, allowing for easier mobile use.
  • the height is substantially up to 120 mm, since the largest available on the market 100 ml drop bottle, for example, has a height of 120 mm and thus easily fits into such an inner compartment.
  • the interior of the medicament compartment may have a width of substantially up to 80 mm, preferably of substantially up to 60 mm, and / or a depth of substantially up to 80 mm, preferably of substantially up to 60 mm. These dimensions serve the same purpose as just explained, the aim is to produce the drug delivery device in an optimal size.
  • the measures referred to above with respect to the medicament compartment may be reflected in compatible dimensions of the interior of the base body described above.
  • the interior of the basic body according to the invention preferably has dimensions in order to be able to receive one or more medicament compartments described here.
  • the medication compartment can have an open top side and / or at least one side wall which is open at least in part, preferably substantially halfway.
  • an expansion module for a drug delivery device has an interior space for accommodating at least one medicine compartment, a directional specification means which permits a movement of the at least one medication compartment in the interior only in one direction and a connection means for, preferably irreversible, connection of the expansion module to a base body.
  • the connecting means between the main body, which here represents the base module, and the supplementary module is preferably chosen so that it can not be separated by the user. This prevents, for example, users from accidentally disconnecting a module and not taking the medication contained therein.
  • the connecting element between basic module and supplementary module is thus preferably such that a complete and correct intake of the medication leads to a maximum of good effect on the patient.
  • a plurality of expansion modules can also be attached, as it were, "in series” to the base body, each extension module having the same connectivity for connection to the main body or the "preceding" expansion module.
  • the interior of the expansion module is preferably configured such that, when the expansion module is connected to the base body, an overall interior results, through which the at least one medicine compartment can be pushed. As a result, as described above, further administration times can be added as needed. So that the sliding function of the drug delivery device continues to function with an expansion module, the interior of the expansion module preferably has the same dimensions as the interior of the base body.
  • the present invention also provides a drug delivery device comprising a body and at least one medication compartment as described above, which components may comprise all or part of the features described above.
  • the system is designed as a modular supplementable "tunnel" with rolling through this tunnel inner compartments, which in principle allows an "infinite” approach.
  • the next correct taking time always comes automatically at the front next.
  • the inner compartment is pushed back in at the back, at the same time positioning the next inner compartment in front.
  • the inner compartments are held in front by a sliding closure, which is operated by hand. In the other direction, all inner compartments are automatically prevented from slipping out by a directional biasing means in the tunnel.
  • the illustrated drug delivery device has a substantially cuboid base body 1 with a tunnel-shaped interior, ie, the basic body 1 shown is open to both end faces.
  • the main body 1 off Fig. 1 offers space for three inner compartments 4 (hereafter referred to as medicine compartments). It should be noted, however, that basic body 1 according to the invention can also be designed for any other number of internal compartments 4.
  • Fig. 1 further shows an expansion module 2, which can be connected to the base body 1 (see below) to make room for an additional inner compartment 4.
  • each viewing window On one longitudinal side of the main body 1 and the expansion module 2 each viewing window are arranged.
  • the medicine compartments 4 have on their front side a surface for applying a label (in Fig. 1 not shown). Thus, when a medication compartment 4 is placed in the body 1, the identification through the viewing window is visible to the user.
  • FIG. 1 a closure device 3, which is attached to the base body 1 near a front side.
  • the closure device 3 is used to hold the medicine compartments 4 within the interior of the main body 1. Specific embodiments of the closure device 3 will be explained in more detail below.
  • Fig. 2 shows perspective views of the embodiment according to Fig. 1 , namely a front view ( Fig. 2a ), a rear view ( Fig. 2b ) and a view of the front side or removal side ( Fig. 2c ).
  • Fig. 3 are also frontal views ( Fig. 3b and 3c ) as well as a section ( Fig. 3a ) by the drug delivery device.
  • the expansion module 2 or more expansion modules 2
  • a total interior through which a plurality of (in Fig. 3 maximum four) drug compartments 4 are pushed past.
  • the Fig. 3 dimensions shown are merely exemplary understood, but the present invention is not limited thereto.
  • Fig. 4a Partial base body 1 shown has on the top of its footprint (ie, in the interior) a wedge-shaped element 5, which serves as a return protection.
  • Fig. 4b partially shown medication compartment 4 also has a wedge-shaped element 9 on its underside.
  • the medication compartment 4 can be pushed through the base body 1 only in a predetermined direction. If the medication compartment 4 is pushed in the other direction, the two elements 5 and 9 engage with each other, so that the medicine compartment 4 can not be moved further.
  • Fig. 4c shown is shown.
  • the wedge-shaped element 5 of the body 1 is designed resiliently.
  • a kind of tongue is preferably formed by a U-shaped recess 6, on which the wedge-shaped element 5 of the base body 1 is mounted.
  • anti-rotation 7 or 10 may preferably be attached both to the base body 1 and to the medicine compartments.
  • These anti-rotation devices are on the one hand formed by two longitudinally extending rails or runners 7 on the base body 1 and on the other hand by a longitudinally extending and open at the ends depression or trough 10 on the drug compartment 4.
  • the runners 7 and the tub 10 are laterally offset in each case with respect to the central axis, preferably by about 5 mm, as in Fig. 4d exemplified.
  • Fig. 4e shows an alternative embodiment of a rotation.
  • the medicine compartment 4 has an asymmetrical shape and the interior of the main body 1 is formed complementary to this asymmetry.
  • Fig. 5 is again the wedge-shaped element 5 described above, and the U-shaped recess 6 is shown. Additionally are in Fig. 5 Guide surfaces 11 are shown, which are described below. It should be noted that the present invention provides embodiments in which all or even only parts of the above aspects are realized.
  • the guide surfaces 11 and runners cause the drug compartments 4, the cross-section is preferably slightly narrower than the interior of the body 1, when inserted into the base body 1 in the correct position and can be easily inserted into this.
  • the guide surfaces 11 fulfill a stabilizing guiding function in the extension of a supplementary module 2 for correct locking. Namely, it is ensured by the guide surfaces 11 when the medication compartment 4 is inserted that, in particular, the body of the supplementary module 2 can not be pushed inwards on the long sides while holding it inwardly, thereby causing incorrect latching.
  • FIG. 6 An embodiment of inventive connecting means 12 and 13 for the main body 1 and an expansion module 2 will be explained.
  • section of the transition between the base body 1 and expansion module 2 is a catch by laterally attached hooks 12 and 13. So if you want to connect an expansion module 2 to the base 1, these two hooks 12 and 13 must engage with each other.
  • Fig. 6a and 6b lateral tongue and groove connections are shown, so that the sides of the base body 1 and the expansion module 2 when latched by the hooks 12 and 13 optimally engage each other.
  • a medication dispenser is shown in the closed state, that is, the closure device 3 is positioned so that no drug compartment 4 can be pushed out of the base body 1.
  • the closure device 3 is a device which consists of three preferably substantially cuboid sections; two preferably the same length, Same width, and equal parts, which are located on the sides of the body 1, are mounted substantially perpendicular to a third portion, which is located on the base body 1.
  • the portion of the closure device 3 on the upper side of the main body 1 preferably overlaps the medicament compartment 4 (as in FIG Fig. 7b shown).
  • the closure device 3 lies completely on the base body 1 and the front side 14 of the section on the upper side of the base body 1 is positioned so that it projects beyond the medication compartment 4. As a result, the medication compartment 4 is blocked and can not be removed from the interior of the body 1.
  • a drug delivery device is shown in the open state, that is, the closure device 3 is positioned so that a medication compartment 4 can be pushed out of the main body 1.
  • the closure device 3 may preferably no longer rest on the base body, whereby the medicine compartment 4 is no longer blocked.
  • the closure device 3 also here preferably comprises three sections, as described in detail above. Closed is the drug delivery device when the closure device 3 rests on the base body 1 (see Fig. 8a and 8c ). It is open when the closure device 3, the top of the base body 1 is not affected (see Fig. 8b and 8d ).
  • the opening and closing is achieved in this embodiment, preferably by a respective detent point 15 at the front and the back of the base body 1 and two corresponding depressions 16 on the front and back of the closure device 3. If the medicament dispensing device is therefore closed, the latching point 15 is in engagement with the upper of the two depressions 16. If the closure device is open, the latching point 15 engages with the lower recess 16.
  • Fig. 9 the detent point 15 is explained in more detail. So that it can be sunk during the pushing up of the closure device 3, the detent point 15 designed resilient.
  • a kind of tongue is preferably formed by a U-shaped recess (see Fig. 9a ) on which the latching point 15 is mounted.
  • the locking point 15 can be moved from the lower recess 16 in the upper recess 16 (see Fig. 9c ).
  • a corresponding guide rail 18 is attached to the closure device 3 (see Fig. 9d ), on the base body 1 is a corresponding groove 17 ( Fig. 9b ).
  • FIG. 10a shows an exemplary holder 19 in side view, in Fig. 10b the resulting depression is filled with a base 21.
  • a guide runner 11 as explained above is shown.
  • Fig. 10c shows a detailed view of a holder 19 with and without stand 21.
  • Fig. 10d For the sake of clarity, the entire system is shown from below.
  • the medicament compartment 4 preferably has a maximum height of substantially 140 mm, which makes it possible to store a plurality of 140 mm long blisters in the medicament compartment 4.
  • the drug delivery device as a whole becomes relatively large and, depending on the size of the blisters, it may be difficult to access the drug compartment 4.
  • the medication compartment 4 preferably has a mean height of substantially 120 mm, whereby several larger blisters with a length of up to 140 mm can be placed diagonally in the medication compartment 4.
  • the medication compartment 4 has a compact height of substantially up to 100 mm.
  • it is suitable for standard blisters (100 mm in length), as well as for standard bottles (100 ml volume). Diagonally, even 120 mm blisters can be stored. Larger blisters can be stored by kinking or cutting.
  • Variant 4 is suitable for standard bottles with up to 100 ml volume.
  • FIG. 12 Different variants of a closure device 3 are shown. So can in Fig. 12a the edges of the closure device 3 are designed differently, for example, laterally projecting for improved gripping or rounded for a more appealing appearance.
  • Fig. 12b various other possible embodiments of the closure device 3 are shown. This is a device which is mounted on the upper side of the main body 1 and protrudes beyond the medicament compartment 4 in the form of a "rocker". When pressure is exerted on the rear part of the closure device, the front side of the closure device moves upwards so that the medicine compartment can be pushed out of the base body.
  • This device can be presented in various forms, for example as a ring or as a kind of "bottle opener”.
  • Fig. 12C shows further possible embodiments of the closure device 3, namely, for example, as a lockable latch, lockable screw cap or sliding closure.
  • the system according to the invention offers the highest level of drug therapy safety (AMTS) through a multiplicity of through-composed, interlinked unique selling points, which lead to an extremely simple operation by the patient in everyday life.
  • AMTS drug therapy safety
  • the system according to the invention is not a conventional pill box. In pill boxes fit (as in new blistering) only pills into it, but not drops, airway sprays, suppositories, sensitive drugs (light, humidity, oxidation, ...), ointments, etc.
  • the system of the invention fit as the only system all drugs all dosage forms, in their approved and therefore safe original packaging.
  • AMG German Medicines Act
  • the system can also take the actual correct intake times according to the leaflet (eg one hour before breakfast, one hour before lunch, to lunch, etc.) correctly represent.
  • the internal dimensions of the medicine compartments have been optimized by means of extensive studies in order to be able to accommodate all common sizes of original packaging in order to ensure their safety required by the AMG, while at the same time remaining as small as possible easy mobile use of the box (eg on vacation) to allow. Furthermore, these inner compartments are optimized for easy removal by older people in practical experiments in which these are not only open at the top, but in addition one of the side walls is half open. Only the system according to the invention allows a sorting of all drugs in the original packaging according to the correct intake times, while at the same time easy handling of the system. In addition, the intake times can be visualized using an intuitive color system. If the medication is changed later, the modules can easily be adapted to the new situation by means of colored plug-in cards or self-adhesive labels.
  • the inner compartments can be held on one side in the direction of removal of the same by a sliding closure. In the other direction, barbs preferably ensure that they fall out, into which corresponding barbs on the inner compartments engage when they are pushed into the tunnel. So only one direction of movement is possible.
  • the inner compartments glide to minimize friction, preferably on runners in the interior of the tunnel.
  • the tunnel consists, as already explained above, of a base module with a sliding closure.
  • This can be extended by individual clip-on supplement modules, each of which depicts another time of administration.
  • two such supplementary modules would therefore have to be clipped.
  • the push-through of the inner compartments is also given in this modular supplement.
  • the connectivity between basic and supplementary module or between supplementary modules themselves is preferably the same and can not be separated by the user again.
  • each meal has its own typical base color, which changes from light to dark as the day progresses, for example blue for evening. This base color also changes from light to dark (gradient) according to the order before, during and after the meal. So you can intuitively recognize by the color of the meal, and in addition, whether the intake or application before, at or after this meal takes place.
  • the color code is used in an accompanying medication plan and can be used on labels on medicine boxes for easy sorting. This allows a correct sorting and operation also for foreign-language fellow citizens or for functional illiterates. Likewise, this color code can be used for easy interfacing with any medication management software, e.g. by optical output or confirmation on a touch screen.
EP15186599.5A 2015-09-24 2015-09-24 Dispositif de distribution de medicaments et corps de base, tiroir a medicament et module d'extension pour un dispositif de distribution de medicaments Active EP3146956B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES15186599T ES2741318T3 (es) 2015-09-24 2015-09-24 Dispositivo dispensador de medicamentos, así como cuerpo de base, compartimento para medicamentos y módulo de ampliación para un dispositivo dispensador de medicamentos
EP15186599.5A EP3146956B1 (fr) 2015-09-24 2015-09-24 Dispositif de distribution de medicaments et corps de base, tiroir a medicament et module d'extension pour un dispositif de distribution de medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15186599.5A EP3146956B1 (fr) 2015-09-24 2015-09-24 Dispositif de distribution de medicaments et corps de base, tiroir a medicament et module d'extension pour un dispositif de distribution de medicaments

Publications (2)

Publication Number Publication Date
EP3146956A1 true EP3146956A1 (fr) 2017-03-29
EP3146956B1 EP3146956B1 (fr) 2019-05-08

Family

ID=54207321

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15186599.5A Active EP3146956B1 (fr) 2015-09-24 2015-09-24 Dispositif de distribution de medicaments et corps de base, tiroir a medicament et module d'extension pour un dispositif de distribution de medicaments

Country Status (2)

Country Link
EP (1) EP3146956B1 (fr)
ES (1) ES2741318T3 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3308962A (en) * 1965-05-10 1967-03-14 Austin U Bryant Pill organizer and method
GB2122578A (en) * 1982-05-28 1984-01-18 Dennis Bransky Device for dispensing pills and the like
US20050023181A1 (en) * 2001-12-03 2005-02-03 Karin Berghaeuser Storage device for consumption-dependent reception of medicaments
US20060086640A1 (en) * 2004-10-01 2006-04-27 Luciano Robert A Jr Pill assembly for pill packaging and delivery systems

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3308962A (en) * 1965-05-10 1967-03-14 Austin U Bryant Pill organizer and method
GB2122578A (en) * 1982-05-28 1984-01-18 Dennis Bransky Device for dispensing pills and the like
US20050023181A1 (en) * 2001-12-03 2005-02-03 Karin Berghaeuser Storage device for consumption-dependent reception of medicaments
US20060086640A1 (en) * 2004-10-01 2006-04-27 Luciano Robert A Jr Pill assembly for pill packaging and delivery systems

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"US $ Milliarden", 2009, NEW ENGLAND HEALTHCARE INSTITUTE
V. GORENOI ET AL.: "Maßnahmen zur Verbesserung der Compliance bzw. Adherence in der Arzneimitteltherapie mit Hinblick auf den Therapieerfolg", HTA BERICHT, vol. 65, 2007

Also Published As

Publication number Publication date
EP3146956B1 (fr) 2019-05-08
ES2741318T3 (es) 2020-02-10

Similar Documents

Publication Publication Date Title
DE69932437T2 (de) System und gerät zur verteilung von medikamenten
DE60121195T2 (de) Dosierspender
US6413241B1 (en) Per kilo doser
EP2643239B1 (fr) Dispositif de stockage et de mélangeage de substances
DE102006052007A1 (de) Medikamentenbehälter
DE202005020811U1 (de) Verpackungseinheit für den wöchentlichen Medikamenten-Bedarf eines Patienten
DE3818705A1 (de) Einrichtung zur erfassung der zeit der einnahme von medikamenten
EP2435010B1 (fr) Station de cintrage de médicaments
EP3146956B1 (fr) Dispositif de distribution de medicaments et corps de base, tiroir a medicament et module d'extension pour un dispositif de distribution de medicaments
AT521328B1 (de) Medikamentenbehälter
DE19855764A1 (de) Verwendung einer Karpule als Spender sowie Vorrichtung für diese Verwendung
DE69826532T2 (de) Vorrichtung zur organisation des kombinierten gebrauchs von lokalen aerosolen und oralen medikamenten
DE202009018751U1 (de) Verpackung zur Auftitration
DE2018754C3 (de) Packung für Dosierungseinheiten, insbesondere Tabletten, Kapseln u.dgl
EP3709948B1 (fr) Dispositif permettant le remplissage dosé d'un contenant avec un produit de remplissage
DE19836100A1 (de) Vorrichtung zur Aufbewahrung eines Arzneimittelbehälters
EP3492394B1 (fr) Dispositif de remplissage dosé d'une paille pour boisson avec un produit de remplissage
DE4400510A1 (de) Behälter, insbesondere Arzneimittelbehälter
DE102018104120A1 (de) Tablettenspender und Verfahren zum Betrieb eines Tablettenspenders
DE102019134447A1 (de) Verfahren und Vorrichtung zur Darreichung einer Polymedikation
EP3492395B1 (fr) Dispositif et procédé destinés au remplissage dosé de récipients à l'aide d'un produit de remplissage
DE19816312C2 (de) Vorrichtung zum Aufbewahren von Medikamenten
CH710778A2 (de) Wochendispenser für Medikamente.
DE102007004152A1 (de) Vorrichtung und Verfahren zum Befüllen von Patientenblistern
DE1910695A1 (de) Fuer Medikamente und auch als hypodermische Spritze verwendbare Flasche bzw. Ampulle

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170929

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HAN-BUEROGERAETE GMBH & CO. KG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180919

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190205

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1129035

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502015008967

Country of ref document: DE

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190808

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190908

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190808

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190809

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2741318

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200210

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502015008967

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

26N No opposition filed

Effective date: 20200211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190924

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190924

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150924

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1129035

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200924

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200924

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 502015008967

Country of ref document: DE

Owner name: HAN GMBH & CO. KG, DE

Free format text: FORMER OWNER: HAN-BUEROGERAETE GMBH & CO KG, 32051 HERFORD, DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: HC

Owner name: HAN GMBH & CO. KG; DE

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME; FORMER OWNER NAME: HAN-BUEROGERAETE GMBH & CO. KG

Effective date: 20220324

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: HAN GMBH & CO. KG

Effective date: 20220525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230920

Year of fee payment: 9

Ref country code: GB

Payment date: 20230921

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230918

Year of fee payment: 9

Ref country code: DE

Payment date: 20230926

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231019

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230929

Year of fee payment: 9